Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
May 2, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2023 –…
Read morepress release
April 28, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – April 28, 2023 – ObsEva SA (SIX: OBSN), a…
Read morepress release
April 20, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 –…
Read moreJune 29, 2023
May 18, 2022
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840